| Value | ₹853.6 Cr |
|---|
NSE filing, NSE: REMUS. Summary written from the filing by ALFA Finder's alert engine.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹845.65
- Market cap
- ₹996.5 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.9×Sector 47.2×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals H1 FY27 Results: Net Profit ₹24.7 Cr, Up 14.4% YoY
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹24.7 Cr · +14.4% YoY
Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals held its 11th Annual General Meeting on September 29, 2026. Shareholders discussed financial results, dividend declaration, and director appointments.
Other results update announcements
All →Laxmi Dental Results Update
Laxmi Dental posted record Q2FY27 revenue of Rs 795.2 million, with EBITDA up 38.5% year-on-year. Its consolidated PAT after JV share stood at Rs 100.4 million.
Entertainment Network (India) Results Update
ENIL reported Q2 FY27 revenue of ₹117 crore and EBITDA up 9.5% to ₹11.3 crore. Digital losses narrowed 23.3% year-on-year.
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Delton Cables Results Update
Delton Cables reported H1 FY27 revenue of Rs.644.2 Crore, up 62% year on year, and H1 PAT of Rs.20.09 Crore, up 114%. Q2 revenue grew 48% and the order book stood at Rs.471.5 Crore.
- Order book
- ₹471.5 Cr
Trident Results Update
Trident Limited reported Q2 FY27 consolidated net profit of INR 176 crore, up 93% year-on-year. The board also approved a INR 4,650 crore expansion and modernisation programme.
Transrail Lighting Results Update
Transrail Lighting posted Q2 FY27 revenue of Rs. 2,056 crore, up 32% year-on-year. H1 FY27 operating cash flow reached Rs. 435 crore.